Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology

Peptide Comparison

MK-677 vs Tesamorelin + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than MK-677 (Phase 3 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. MK-677 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

MK-677

Phase 3 (not approved)

Tesamorelin + Ipamorelin

FDA-Approved (component)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

MK-677 Tesamorelin + Ipamorelin
Class Oral non-peptide ghrelin receptor agonist FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover.
Route Oral SC injection
Half-life ~24 hrs Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs
Dosage (research) 12.5 mg oral daily (community starting dose to mitigate water retention and appetite increase, escalate to label dose 25 mg/day per MK-0677-014 Phase 3 protocol) 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off
Evidence tier Phase 3 (not approved) FDA-Approved (component)
Research depth 168 indexed (PubMed 114 · CT 8 · EPMC 46) 2 indexed (PubMed 0 · CT 0 · EPMC 2)
Availability Research Chemical Compounding Restricted
Reported risks Increased hunger; water retention; insulin resistance risk; lethargy; CHF risk (elderly trials) Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive)

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick MK-677 or Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than MK-677 (Phase 3 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. MK-677 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between MK-677 and Tesamorelin + Ipamorelin?

MK-677 is classed as Oral non-peptide ghrelin receptor agonist; Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: MK-677, GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine; Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: MK-677, ~24 hrs; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: MK-677, Oral; Tesamorelin + Ipamorelin, SC injection.

Which has stronger evidence, MK-677 or Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MK-677 is graded Phase 3 (not approved), with 5 cited sources on its reference page and 168 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page and 2 indexed studies.

Which is more accessible, MK-677 or Tesamorelin + Ipamorelin?

Neither MK-677 nor Tesamorelin + Ipamorelin is an FDA-approved drug. Catalog status: MK-677, Research Chemical; Tesamorelin + Ipamorelin, Compounding Restricted. FDA lists MK-677 in category 2 of its bulk-substance compounding policy (503A; 503B, added 503A: September 29, 2023 503B: December 29, 2022).

Are MK-677 and Tesamorelin + Ipamorelin ever combined?

MK-677 and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…